ERBB2 and gastric cancer: Recent data from the phase II RCTS trial reported an impressive ORR of 89.4% and a median PFS of 12.7 months with RC48 plus tislelizumab and S‐1 chemotherapy as first‐line therapy in patients with advanced GC (HER2 IHC ≥ 2+).